Skip to content

Unilife Medical Solutions

Results of Scheme Meetings and Extraordinary General Meeting
11 January 2010

In accordance with ASX Listing Rule 3.13.2, Unilife Medical Solutions Limited (Unilife or the Company) (ASX: UNI / OTCPK: UNIFF) is pleased to confirm that each of the resolutions put to shareholders and optionholders at the Court Ordered Scheme Meeting of Shareholders and Optionholders (as applicable) and the Extraordinary General Meeting held on 8 January 2010 were passed.

The resolutions related to the following matters:

SHARE SCHEME MEETING

  1. Approval of Share Scheme - Approximately 99% in favour.

OPTION SCHEME MEETING

  1. Approval of Option Scheme - 100% in favour.

EXTRAORDINARY GENERAL MEETING

  1. Approval of Unilife Corporation 2009 Stock Incentive Plan - Unanimously passed on a show of hands. Approximately 91% of proxies in favour1;
  2. Approval of issue of options to Jeff Carter - Unanimously passed on a show of hands. Approximately 88% of proxies in favour1;
  3. Approval of issue of options to John Lund - Unanimously passed on a show of hands. Approximately 85% of proxies in favour1;
  4. Approval of issue of options to William Galle - Unanimously passed on a show of hands. Approximately 84% of proxies in favour1; and
  5. Approval of issue of incentives to Alan Shortall - Unanimously passed on a show of hands. Approximately 84% of proxies in favour1.

Further details of the results of the resolutions are set out in the attachment.

Comment from Unilife Chief Executive Officer Alan Shortall

"Shareholders have voted overwhelmingly in favour of our redomiciliation to the US. We consider this to be a resounding vote of shareholder confidence in our plans to consolidate our position as a US-based global leader in the design, development and supply of innovative safety medical devices.

"We are now in a position to finalise preparations to list on the NASDAQ stock exchange. Subject to the SEC declaring our registration statement effective and NASDAQ approving our listing application, trading on the NASDAQ exchange is expected to commence in mid-February.

"I believe these steps will help consolidate our position as a sustainable global business with the necessary expertise and operational capabilities to service the needs of an expanding network of pharmaceutical and healthcare customers. It will also help us build relationships with US-based investors that have a firm understanding of global pharmaceutical and healthcare markets.

"The Board and I are confident that Unilife will continue to deliver upon key commercial and operational milestones for 2010. Over the coming 12 months we intend to complete our listing on NASDAQ, expand our base of US investors, complete the industrialisation program for the UnifilTM 1mL syringes, strengthen our relationships with pharmaceutical and healthcare industry leaders, complete our new global headquarters in Pennsylvania and continue to build a world-class team. We look forward to building further value in the Company on behalf of all our shareholders."

Unilife would also like to take this opportunity to inform shareholders and optionholders that Federal Court approval of the Schemes will be sought at 2.15pm on Thursday 14 January 2010 at Law Courts Building, Queens Square, Sydney, New South Wales.


Shareholder / Analyst Enquiries:

Australia Jeff Carter Phone: + 61 2 8346 6500
United States Stuart Fine Phone: + 1 908 469 1788

1 The Chairman indicated that he would vote all his open usable votes in favour of each resolution and these have therefore been added to the proxies which were directed “for” the resolutions.

Results of Scheme Meetings and Extraordinary General Meeting Results of Scheme Meetings and Extraordinary General Meeting 42.29 Kb

 

UNILIFE MEDICAL SOLUTIONS LIMITED
SCHEME AND EXTRAORDINARY GENERAL MEETINGS – 8 JANUARY 2009

SHARE SCHEME MEETING

The number of votes cast on poll (including the proxy votes) was as follows:

Number of Shareholders voting  For:
Number of Shareholders voting Against: 
Total Votes For:
Total Votes Against
Total Votes Abstain:
530
46
115,708,938
1,153,823
238,279
(92.01%)
(7.99%)
(99.01%)
(0.99%)
N/A

 
OPTION SCHEME MEETING

The number of votes cast on poll (including the proxy votes) was as follows:

Number of Optionholders voting  For:
Number of Optionholders voting Against: 
Total Votes For:
Total Votes Against
Total Votes Abstain:
4
Nil
10,500,000
0
0
(100%)
(0%)
(100%)
(0%)
(0%)


EXTRAORDINARY GENERAL MEETING

In accordance with section 251AA of the Corporations Act 2001, the following information is provided to Australian Stock Exchange Limited in relation to resolutions passed by members of Unilife Medical Solutions Limited at its extraordinary general meeting held on 8 January 2010.

Resolution 1

Resolution 2

Resolution3

Resolution 4

Resolution 5

Decided by a show of hands (S) or poll (P)

S

S

S

S

S

Total number of proxy votes exercisable by proxies validly appointed

111,351,793

94,861,485

94,861,485

94,861,485

94,861,485

 

Resolution 1

Resolution 2

Resolution3

Resolution 4

Resolution 5

Total number of proxy votes in respect of which the appointments specified that:

1. The proxy is to vote for the resolution

70,631,985

69,846,618

67,200,633

66,662,773

65,606,066

2. The proxy is to vote against the resolution

9,409,093

11,776,083

14,431,193

14,969,053

15,270,932

3. The proxy is to abstain on the resolution

2,074,402

421,044

411,919

411,919

1,166,747

4. The proxy may vote at the proxy’s discretion

29,236,313

12,817,740

12,817,740

12,817,740

12,817,740

 

Resolution 1

Resolution 2

Resolution3

Resolution 4

Resolution 5

Total votes cast on a poll in favour of the resolution

N/A

N/A

N/A

N/A

N/A

Total votes cast on a poll against the resolution

N/A

N/A

N/A

N/A

N/A

Total votes cast on a poll abstaining on the resolution

N/A

N/A

N/A

N/A

N/A

Total votes exercisable by proxies which were not cast

N/A

N/A

N/A

N/A

N/A

 
 

HomeSite MapContact Us Top